Pharmacogenetics of the Glucagon-like Peptide-1 Receptor Agonist Liraglutide: A Step Towards Personalized Type 2 Diabetes Management.
Title | Pharmacogenetics of the Glucagon-like Peptide-1 Receptor Agonist Liraglutide: A Step Towards Personalized Type 2 Diabetes Management. |
Publication Type | Journal Article |
Year of Publication | 2021 |
Authors | Kyriakidou, A., Koufakis T., Goulis D. G., Vasilopoulos Y., Zebekakis P., & Kotsa K. |
Journal | Curr Pharm Des |
Volume | 27 |
Issue | 8 |
Pagination | 1025-1034 |
Date Published | 2021 |
ISSN | 1873-4286 |
Keywords | Diabetes Mellitus, Type 2, Glucagon-Like Peptide-1 Receptor, Humans, Hypoglycemic Agents, Liraglutide, Pharmacogenetics |
Abstract | BACKGROUND: Type 2 Diabetes Mellitus (T2DM) is a chronic metabolic disorder with increasing prevalence and a significant burden of long-term complications. Glucagon-like Peptide-1 receptor agonists (GLP-1 RAs) are a novel treatment option for T2DM, exerting optimal effects on glucose control and weight loss, and pleiotropic actions. Pharmacogenetics, a promising research field of precision medicine, investigates how gene variations can affect individual response to drug therapy, assuming that the diverse genetic architecture of patients with T2DM could be partly associated with the considerable inter-individual variability in the therapeutic response to GLP-1 RAs. This review aims to summarize current evidence related to T2DM risk variants, affecting the incretin pathway, focus on the pharmacogenetics of the GLP-1 RA liraglutide, and discuss their potential clinical implications in the management of this complex disorder. |
DOI | 10.2174/1381612826666201203145654 |
Alternate Journal | Curr Pharm Des |
PubMed ID | 33272167 |